Molecular determinants of response to PD-L1 blockade across tumor types

Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis lead to durable clinical responses in subsets of cancer patients across multiple indications, including non-small cell lung cancer (NSCLC), urothelial carcinoma (UC) and renal cell carcinoma (RCC). Herein, we complement PD-L1 immunohistochem...

Descripción completa

Detalles Bibliográficos
Autores principales: Banchereau, Romain, Leng, Ning, Zill, Oliver, Sokol, Ethan, Liu, Gengbo, Pavlick, Dean, Maund, Sophia, Liu, Li-Fen, Kadel, Edward, Baldwin, Nicole, Jhunjhunwala, Suchit, Nickles, Dorothee, Assaf, Zoe June, Bower, Daniel, Patil, Namrata, McCleland, Mark, Shames, David, Molinero, Luciana, Huseni, Mahrukh, Sanjabi, Shomyseh, Cummings, Craig, Mellman, Ira, Mariathasan, Sanjeev, Hegde, Priti, Powles, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233428/
https://www.ncbi.nlm.nih.gov/pubmed/34172722
http://dx.doi.org/10.1038/s41467-021-24112-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233428/
https://www.ncbi.nlm.nih.gov/pubmed/34172722
http://dx.doi.org/10.1038/s41467-021-24112-w

Ejemplares similares